Coagulation Factor Deficiency

2

Review clinical trials related to Coagulation Factor Deficiency. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

SWIFT - SWIss Factor XIII Trial in PPH

The goal of this trial is to determine if postpartum blood loss can be reduced by replenishing coagulation factor XIII (FXIII) at an early stage of postpartum hemorrhage (PPH). Summary of current body of evidence: * Morbidity and mortality due to PPH is rising. * Current guidelines focus on replenishment of fibrinogen as an initial step in the treatment of PPH-related coagulopathy, despite non-conclusive evidence in all prospective trials. * Trials from other specialties demonstrate a significant impact of FXIII on perioperative bleeding complications; a previous study at the University Hospital Zurich showed that pre-partum factor XIII activity had a strong association to postpartum blood loss. Therefore, this nationwide, multi-center, randomized, controlled trial in multiple perinatal centers across Switzerland will be conducted. The goal is to determine if postpartum blood loss and PPH-related complications can be reduced by replenishing FXIII. All participating women receive, according to the national guideline, 1g tranexamic acid (TXA) i.v. in case of PPH (measured blood loss \[MBL\] ≥ 500 mL) during the pre-study phase. Randomization takes place if bleeding continues and exceeds 700mL. The intervention group then receives FXIII (Fibrogammin®) according to approved dosage in addition to obstetric standard of care treatment for causes of PPH; the control group receives only standard of care treatment.

Participants needed: 988
Trial details
Phase: Phase 4Age: 18+Biological sex: FemaleType: InterventionalSponsor: Christian HaslingerUpdated: Apr 27, 2026Locations: 9
Eligibility criteria

planned vaginal delivery [+3]

Antithrombotic therapy in pregnancy (therapeutic dosage) until admission for del... [+14]

Status: Recruiting

Longitudinal Cohort of Thrombosis and Hemostasis Diseases

This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic information, diagnostic and treatment information, as well as medical expense information of patients from medical records.The incidence and risk factors of thrombosis and hemostasis diseases, the treatment methods, prognosis and medical expenses of these patients in China will be analyzed. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.

Participants needed: 3,000
Trial details
Biological sex: AllType: ObservationalSponsor: Peking University People's HospitalUpdated: Dec 11, 2024Locations: 5Duration: 5 Years
Eligibility criteria

Patients who were diagnosed as thrombosis and hemostasis diseases.

Long-term follow-up information for patients is not available for any reason, su... [+2]